Peripheral T-cell Lymphoma

P3, N=114, Enrolling by invitation, N.N. Petrov National Medical Research Center of Oncology

P1, N=12, Terminated, Henan Cancer Hospital | Phase classification: P1/2 --> P1 | Trial completion date: Feb 2025 --> Aug 2025

P=N/A, N=88, Recruiting, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

This case series found that JAK2 fusions were seen in aggressive cytotoxic CTCL as well as in T-cell lymphomas with more indolent behavior, possibly representing a precursor lesion to aggressive evolution with age and comorbidities. The prominence of these fusions supports a potentially larger role for JAK2 targeting in patients with early-stage MF, CD30-positive LPD, or overlap presentations.

Importantly, pharmacological inhibition of USP1 with ML323 effectively enhances PTCL cell sensitivity to doxorubicin, suggesting a promising therapeutic strategy to improve treatment outcomes in PTCL patients. Collectively, we have found that USP1 represents a compelling therapeutic target for addressing chemoresistance and improving outcomes in PTCL therapy.

EBV infection appears to influence disease progression and prognosis in EBER-positive patients, whereas EBER-negative cases more closely align with the disease characteristics observed in other peripheral T-cell lymphomas. The results suggest that stratifying patients by EBV status is crucial for optimizing AITL clinical management.

P3, N=218, Recruiting, Dizal Pharmaceuticals

This case highlights the diagnostic challenge posed by rare penile lesions and, more importantly, the therapeutic dilemma of selecting an appropriate treatment for a disease that is localized yet multifocal. The successful outcome with systemic brentuximab vedotin plus cyclophosphamide, doxorubicin, vincristine, and prednisone therapy, a deviation from standard guidelines for unifocal primary cutaneous anaplastic large cell lymphoma, underscores the need for individualized treatment strategies and further research to establish risk-adapted guidelines for this rare clinical entity.

This case was classified as monomorphic T/NK-cell post-transplant lymphoproliferative disorder and peripheral T-cell lymphoma, not otherwise specified, in the fourth and fifth World Health Organization classifications, respectively. Further research is required to clarify the association between immunosuppression and lymphoproliferative disorders.

This study is the first to construct a survival prediction model for ALCL-ALK positive using a multi-algorithm ensemble strategy. The model offers a practical tool for individualized risk assessment and may aid in optimizing clinical decision-making.

P2, N=48, Active, not recruiting, City of Hope Medical Center | Trial completion date: Aug 2025 --> Jul 2026

PNI and SIRI have certain application value in evaluating short-term efficacy and prognosis in patients with PTCL. Compared with SIRI, PNI demonstrates greater predictive value for patient prognosis.